Professionals 248 Users Online

Anti-Bleeding Gel Market

Anti-Bleeding Gel Market Size, Trend and Growth Forecast by Product Type, by Indication, by Distribution Channel, and by Region for 2024-2031

Anti-Bleeding Gel Market Size and Share Analysis

The global anti-bleeding gel market is estimated to value at US$9.2 Bn by the end of 2031 from US$6.1 Bn estimated to be recorded in 2024. The market is expected to secure a CAGR of 6.1% in the forthcoming years from 2024 to 2031.

Market Attributes

Key Insights

 Market Size (2024E)

US$6.1 Bn

Projected Market Value (2031F)

US$9.2 Bn

Value CAGR 2024 – 2031

6.1%

Value CAGR 2019 – 2023

5.7%

Sample Report

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Download PDF Get FREE Report Sample

Anti-Bleeding Gel Market Introduction and Trend Analysis

Anti-bleeding gels, also referred to as hemostatic gels, are medical products devised to swiftly halt bleeding from wounds, cuts, and surgeries. They function by expediting the natural blood clotting process, effectively managing bleeding more efficiently than traditional methods like bandages, or gauze.

Widely utilized across medical disciplines such as emergency care, surgery, dental procedures, and even in military and sports settings, these gels typically contain agents like chitosan, fibrin, and clotting factors to promote hemostasis.

Some variants even integrate antimicrobial properties to deter infections. Applied directly to wounds, these gels create a protective barrier, not only arresting bleeding but also shielding the wound from contaminants.

The anti-bleeding gel market has witnessed substantial growth owing to increased awareness about advanced hemostatic products, a surge in trauma cases and surgeries, and advancements in medical technology.

This market is anticipated to continue growing at a significant CAGR in the coming years. Driven by technological progress, expanding applications in surgical and emergency scenarios, and heightened awareness and acceptance of sophisticated hemostatic solutions, the anti-bleeding gel market is poised for considerable expansion.

Companies in this sector must navigate regulatory complexities and high costs while capitalizing on opportunities in emerging markets and fostering product innovations to maintain their competitive advantage.

Historical Growth and Course Ahead

Early hemostatic products included basic gauze and bandages, which had limited efficacy in controlling severe bleeding. The development of chitosan-based products in the 1980s represented a significant advancement, offering improved bleeding control.

The introduction of advanced hemostatic agents like fibrin sealants and thrombin-based products followed, along with the adoption of anti-bleeding gels in military settings. These gels became crucial in responding to battlefield injuries during conflicts such as the Iraq and Afghanistan wars, emphasizing the need for rapid hemostasis.

As the global population ages and chronic diseases become more prevalent, the number of surgeries is expected to rise, leading to increased demand for effective hemostatic solutions like anti-bleeding gels.

Continuous research and development efforts are anticipated to lead to the launch of more efficient, faster, and user-friendly anti-bleeding gels. Innovations such as bioengineered gels and products with built-in antimicrobial properties will drive the market for anti-bleeding gels.

Key Trends and Innovations Shaping the Market

  • Growing preference for minimally invasive surgical procedures that require efficient, and rapid hemostasis
  • Continuous innovation, and adoption of advanced hemostatic products in the military and defense sectors for battlefield injuries
  • Development of bioengineered gels that mimic natural clotting mechanisms to enhance effectiveness
Custom Report Cover

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

> Get a Customized Version

Market Growth Drivers

Enhanced Emergency Medical Services

Advanced emergency medical services (EMS) play a vital role in driving growth in the anti-bleeding gel market. Progress in EMS protocols, equipment, and training significantly influences the demand and acceptance of efficient hemostatic solutions such as anti-bleeding gels.

Modern EMS systems prioritize rapid response to trauma incidents, and the swift application of anti-bleeding gels in pre-hospital settings can effectively manage severe bleeding, stabilize patients, and enhance survival rates.

Updated EMS protocols now incorporate the use of hemostatic agents for severe bleeding, making anti-bleeding gels a standard component of trauma care. Integration of anti-bleeding gels into standard first responder kits is on the rise.

This ensures that paramedics and emergency medical technicians (EMTs) can promptly administer these gels to control bleeding at the accident or injury site.

Products such as pre-filled syringes and sprays facilitate quick and easy application, making them ideal for emergency scenarios where time is of the essence.

The expansion of enhanced EMS significantly drives growth in the anti-bleeding gel market. By incorporating advanced hemostatic products into trauma care protocols, training initiatives, and first responder kits, EMS systems globally are enhancing patient outcomes during emergencies.

This trend not only spurs market demand but also encourages continuous innovation and the development of more efficient and user-friendly hemostatic solutions.

Market Research Methodology

Market Research Methodology

-Perfect through Years of Diligence

Check Research Methodology

Factors Impeding the Market Growth

High Costs of Advanced Anti-bleeding Products

The substantial expenses linked to advanced hemostatic products, such as anti-bleeding gels, represent a notable impediment to market expansion. This financial barrier affects various stakeholders, including healthcare providers, patients, and insurance companies, impacting the uptake and widespread utilization of these sophisticated medical solutions.

The development of advanced hemostatic gels necessitates significant investment in research and development to ensure effectiveness, safety, and regulatory compliance. These costs are typically transferred to consumers, resulting in higher-priced end products.

Rigorous clinical trials are essential to establish the safety and efficacy of these products, adding to the overall cost and time required. The elevated costs associated with advanced hemostatic products such as anti-bleeding gels pose a considerable hindrance to market growth.

Overcoming this challenge entails strategic initiatives in cost-efficient manufacturing, streamlining regulatory processes, securing financial backing, and embracing innovative pricing strategies.

By addressing these cost-related obstacles, the market can facilitate broader adoption and accessibility, ultimately benefiting a wider spectrum of patients and healthcare providers.

Sales Team

Sales Team
Client Partner

Let's Connect

Connect me to identify winning opportunities

Ask An Expert
I'm Available

Future Opportunities for Anti-Bleeding Gel Companies

Technological Advancements

Utilizing sensors to detect clotting status and adjust gel properties for optimal hemostasis, along with gathering data on clotting dynamics and patient response for personalized treatment strategies, represents innovative advancements in the field of anti-bleeding gels.

Smart gels that respond to specific bleeding characteristics, such as clotting time or blood flow rate, are another cutting-edge development.

Moreover, integrating components that promote tissue regeneration alongside hemostasis can enhance wound healing outcomes significantly. The incorporation of such advanced technologies into anti-bleeding gel initiatives offers substantial opportunities to enhance engagement, customization, and effectiveness.

Anti-bleeding gel companies can offer more comprehensive and efficient wellness solutions by leveraging technologies such as wearables, blockchain, artificial intelligence (AI), virtual reality (VR), telemedicine, mobile applications, big data analytics, and gamification.

This technological integration can lead to market growth by improving employee health outcomes, increasing participation rates, and enhancing overall satisfaction with wellness programs.

Category-wise Analysis

Category

Projected CAGR through 2031

Product - Veterinary Use

 6.5%

Indication - Trauma

 7.1%

Distribution Channel - Retail Pharmacy

 7.5%

Veterinary Anti-Bleeding Gels Surge Ahead

Animals often experience trauma or injuries that result in bleeding, requiring quick and effective hemostatic solutions. Anti-bleeding gels provide a rapid means to control bleeding, which is essential in emergency veterinary care.

Products like VETIGEL® have been specifically designed for the veterinary market and have demonstrated significant effectiveness in stopping bleeding quickly without the need for manual pressure. This innovation has made such products highly sought after in veterinary practices?.

There is a high demand for effective hemostatic agents in various veterinary procedures such as surgeries, wound treatment, and emergency care. The need for rapid and reliable bleeding control solutions drives the prominence of these products in the veterinary market?.

The combination of immediate applicability, regulatory advantages, high demand in veterinary care, and targeted product development has made veterinary use the leading category in the anti-bleeding gel market.

Trauma to be the Largest Indication Category

Trauma is one of the leading causes of morbidity and mortality worldwide, especially from road accidents, falls, and other physical injuries. The frequent occurrence of traumatic events creates a substantial need for effective and rapid hemostatic agents to control bleeding and improve survival rates in both prehospital and hospital settings.

In trauma cases, time is of the essence. Rapid control of bleeding can be life-saving, as excessive blood loss is a primary cause of death in traumatic injuries. Anti-bleeding gels provide a quick and efficient solution to stop bleeding, making them highly valuable in emergency trauma care.

The high incidence of traumatic injuries, urgent need for rapid hemostasis, widespread use in emergency medicine, product innovations, supportive regulatory environment, and economic considerations collectively contribute to the prominence of trauma as the leading indication in the anti-bleeding gels market.

Retail Pharmacy Tops Distribution Charts

Retail pharmacies are widely accessible to the general public, providing a convenient location for consumers to purchase medical products, including anti-bleeding gels. This ease of access ensures that individuals can quickly obtain these products when needed, particularly in emergencies.

Consumers tend to trust retail pharmacies for their medical needs due to the professional oversight provided by pharmacists. The familiarity and established trust in these outlets make them a preferred choice for purchasing medical products, including hemostatic agents.

Many retail pharmacies are integrated with other health services, such as clinics and primary care facilities, further promoting their use as distribution points for medical products. This integration allows for a comprehensive approach to health management, where patients can receive prescriptions and over-the-counter solutions in one place.

The prominence of retail pharmacies as a distribution channel for anti-bleeding gels is driven by their accessibility, consumer trust, immediate availability, professional guidance, integration with health services, and extensive market reach. These factors collectively contribute to the widespread adoption and use of anti-bleeding gels through retail pharmacy channels.

Region-wise Analysis

Region

Projected CAGR through 2031

North America

 6.8%

South Asia & Pacific

 7.5%

Advances in Medical Devices and Biotechnology Uphold North America’s Lead

North America boasts advanced healthcare infrastructure, including hospitals, clinics, and research institutions. This infrastructure supports the development, production, and distribution of anti-bleeding products.

The region is at the forefront of technological advancements in medical devices, pharmaceuticals, and biotechnology. This includes the development of hemostatic agents, clotting factors, and other anti-bleeding treatments.

Companies in North America have relatively easier access to venture capital, private equity, and government grants for research and development in the healthcare sector, including bleeding disorder treatments.

These factors collectively contribute to North America's leadership in the anti-bleeding market, driving innovation, accessibility, and quality of care for patients with bleeding disorders in the region.

Asia Pacific Gains from Growing Awareness About Bleeding Disorders

Asia Pacific has a significant population base, which includes a substantial number of individuals with bleeding disorders such as hemophilia, and von Willebrand disease. This large patient population drives demand for anti-bleeding products and treatments.

Many countries in the Asia Pacific region are experiencing rapid economic growth and increasing healthcare expenditure. This growth enables greater access to advanced medical treatments, including anti-bleeding therapies.

There is growing awareness about bleeding disorders in the Asia Pacific region, leading to improved diagnosis rates. As more individuals are diagnosed with these conditions, the demand for anti-bleeding products, including hemostatic agents and factor replacement therapies, increases.

Overall, the Asia Pacific region's leadership in the anti-bleeding market is driven by factors such as a large patient population, improving healthcare infrastructure, rising awareness, government support, technological advancements, and opportunities in emerging markets.

Competitive Landscape Analysis

Collaborations and partnership to develop innovative products and accelerate the grant by regulatory bodies are the key growth strategies followed by the key players in the market. Companies are continuously investing in research and development to introduce innovative and break-through Anti-bleeding gel products. 

Top Industry Players in the Global Anti-bleeding Gel Market

  • Cresilon Inc.
  • Baxter Healthcare Corporation
  • Z-Medica
  • Steve Kelly
  • Ethicon
  • Pfizer Inc.
  • CR Bard
  • Hemcon Medical Technologies Inc
  • Abbott Laboratories
  • Johnson & Johnson

Recent Industry Developments

January 2023

Cresilon has introduced a groundbreaking hemostatic gel technology made from plant-based polymers that can stop bleeding without the need for manual pressure. This advanced gel is conveniently applied directly from a pre-filled syringe. The product marketed as Vetigel, has been in use in veterinary medicine. It is currently employed in veterinary surgical procedures as a single-use, prescription gel, demonstrating significant efficacy and convenience.

June 2022

An innovative gel containing two snake venom proteins known to help blood clotting, rapidly and effectively forms stable clots and reduces bleeding even in the presence of a blood-clotting disorder, as is the case in hemophilia, a preclinical study shows. The gel, which transitions to a liquid form below 22 degrees Celsius (about 71.6 degrees Fahrenheit), also was shown not to induce immune reactions against it.

Anti-Bleeding Gel Market Report Scope & Segmentation

Attributes

Details

Forecast Period

2024 to 2031

Historical Data Available for

2018 to 2023

Market Analysis

US$ Billion for Value

Key Regions Covered

  • North America
  • Europe
  • East Asia
  • Asia Pacific
  • Middle East and Africa
  • Latin America

Key Market Segments Covered

  • Product
  • Indication
  • Distribution Channel
  • Region

Key Companies Profiled in the Report

  • Cresilon Inc.
  • Baxter Healthcare Corporation
  • Z-Medica
  • Steve Kelly
  • Ethicon
  • Pfizer Inc.
  • CR Bard
  • Hemcon Medical Technologies Inc
  • Abbott Laboratories
  • Johnson & Johnson         

Report Coverage

  • Market Forecast and Trends
  • Company Share Analysis
  • Competitive Intelligence
  • DROT Analysis
  • Market Dynamics and Challenges
  • Strategic Growth Initiatives  

Customization & Pricing

Available upon request

Anti-bleeding Gel Market Segmentation

By Product

  • Veterinary Use
  • Human Use

By Indication

  • Biopsies of Soft Tissue
  • Trauma
  • Enucleations
  • Orthopaedic Surgeries
  • Others

By Distribution Channel

  • Retail Pharmacy
  • Online Pharmacy
  • Veterinary Pharmacy
  • Others

By Region

  • North America
  • Europe
  • Asia Pacific
  • The Middle East and Africa
  • Latin America

- Companies Covered in This Report -

- Frequently Asked Questions -

Companies differentiate by offering innovative anti-bleeding gels with unique formulations, improved efficacy, faster action, longer duration of effect, and reduced side effects. Novel ingredients, delivery systems, and mechanisms of action contribute to product differentiation.

Some of the key players operating in the market are Cresilon Inc., Baxter Healthcare Corporation, Z-Medica, Steve Kelly, and Ethicon.

Trauma segment records a significant market share as of 2024 in indication category.

There is a growing awareness about bleeding disorders such as hemophilia, von Willebrand disease, and other coagulation disorders in the US. This increased awareness leads to more individuals being diagnosed with these conditions, thereby driving the demand for anti-bleeding products including gels.

The veterinary use segment records a significant market share as of 2024.

This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy
Google translate